Source: European Medicines Agency (EU) Revision Year: 2018 Publisher: Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT, Amsterdam, Netherlands
ABILIFY 7.5 mg/ml solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear, colourless, aqueous solution. |
Each ml contains 7.5 mg of aripiprazole. Each vial contains 9.75 mg aripiprazole.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Aripiprazole |
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors. |
| List of Excipients |
|---|
|
Sulfobutylether β-cyclodextrin (SBECD) |
Each carton contains one single-use type I glass vial with a rubber butyl stopper and a “tear-off” aluminium seal.
Otsuka Pharmaceutical Netherlands B.V., Herikerbergweg 292, 1101 CT, Amsterdam, Netherlands
EU/1/04/276/036
Date of first authorisation: 04 June 2004
Date of latest renewal: 04 June 2009
| Drug | Countries | |
|---|---|---|
| ABILIFY | Austria, Australia, Canada, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
